AP2004002994A0 - Nutrient therapy for immuno-compromised patients - Google Patents

Nutrient therapy for immuno-compromised patients

Info

Publication number
AP2004002994A0
AP2004002994A0 APAP/P/2004/002994A AP2004002994A AP2004002994A0 AP 2004002994 A0 AP2004002994 A0 AP 2004002994A0 AP 2004002994 A AP2004002994 A AP 2004002994A AP 2004002994 A0 AP2004002994 A0 AP 2004002994A0
Authority
AP
ARIPO
Prior art keywords
support
mitochondria
failure
muscle mass
sod
Prior art date
Application number
APAP/P/2004/002994A
Other languages
English (en)
Inventor
Carl Germano
Original Assignee
Millennium Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Biotechnologies Inc filed Critical Millennium Biotechnologies Inc
Publication of AP2004002994A0 publication Critical patent/AP2004002994A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
APAP/P/2004/002994A 2001-08-10 2002-08-09 Nutrient therapy for immuno-compromised patients AP2004002994A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/927,174 US6503506B1 (en) 2001-08-10 2001-08-10 Nutrient therapy for immuno-compromised patients
PCT/US2002/025358 WO2003013438A2 (en) 2001-08-10 2002-08-09 Nutrient therapy for immuno-compromised patients

Publications (1)

Publication Number Publication Date
AP2004002994A0 true AP2004002994A0 (en) 2004-03-31

Family

ID=25454328

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2004/002994A AP2004002994A0 (en) 2001-08-10 2002-08-09 Nutrient therapy for immuno-compromised patients

Country Status (9)

Country Link
US (1) US6503506B1 (cg-RX-API-DMAC7.html)
EP (1) EP1432436A4 (cg-RX-API-DMAC7.html)
JP (1) JP2005501061A (cg-RX-API-DMAC7.html)
CN (1) CN1568196A (cg-RX-API-DMAC7.html)
AP (1) AP2004002994A0 (cg-RX-API-DMAC7.html)
CA (1) CA2457624A1 (cg-RX-API-DMAC7.html)
EA (1) EA006439B1 (cg-RX-API-DMAC7.html)
OA (1) OA12649A (cg-RX-API-DMAC7.html)
WO (1) WO2003013438A2 (cg-RX-API-DMAC7.html)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6616942B1 (en) 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
FR2822704B1 (fr) * 2001-03-29 2005-02-18 Chiesi Sa Sels de cetoacides et d'acides amines gastroresistants et leur utilisation pour la preparation de medicaments
US6503506B1 (en) * 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients
US20080089877A1 (en) * 2003-08-14 2008-04-17 Udell Ronald G Super Absorption Coenzyme Q10
WO2005032278A1 (en) 2003-09-29 2005-04-14 Soft Gel Technologies, Inc. SOLUBILIZED CoQ-10
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
ITTO20030789A1 (it) * 2003-10-07 2005-04-08 Professional Dietetics Srl Composizione a base di amino acidi per il trattamento
ES2677868T3 (es) * 2003-10-16 2018-08-07 Nestec S.A. Composición nutricional frente a los efectos secundarios de la quimioterapia o de la radioterapia
HRP20130459T1 (en) 2004-01-22 2013-06-30 University Of Miami Topical co-enzyme q10 formulations and methods of use
KR20060132667A (ko) * 2004-01-28 2006-12-21 네스텍소시에테아노님 피부 상태 개선 및 피부 질환 예방을 위한 영양 조성물
US20050209170A1 (en) * 2004-03-18 2005-09-22 Takemoto Arnold C Breast health preparations
EP1734978A2 (en) * 2004-03-17 2006-12-27 Arnold C. Takemoto Tissue detoxification and health supplements and methods of making and using them
JP2005336176A (ja) * 2004-04-28 2005-12-08 Tanabe Seiyaku Co Ltd 肉体疲労改善剤
EP1600061B1 (en) * 2004-05-25 2010-05-12 Cognis IP Management GmbH Oral and/or topical compositions
US20050265990A1 (en) * 2004-06-01 2005-12-01 Shawn Talbott Treatments and nutritional supplements for assisting post-exercise recovery
JP5069000B2 (ja) * 2004-06-30 2012-11-07 敦生 関山 非炎症性ストレス応答の指標剤およびその利用
KR100584891B1 (ko) 2004-08-13 2006-05-30 (주)씨스팜 경구용 슈퍼옥사이드 디스뮤타제 제제인, 캔털루프 멜론추출물과 글리아딘 결합물을 숙취해소에 사용하는 방법
US7284385B2 (en) * 2004-09-16 2007-10-23 Hess Spencer W Pre-dried air reactivation for diesel fuel heated dessicant reactivator
JP5040060B2 (ja) * 2004-10-14 2012-10-03 大正製薬株式会社 メチオニン配合内服液剤
US20060147550A1 (en) * 2004-12-30 2006-07-06 Gorsek Wayne F Immune system enhancement and stimulation formulation
US20070114476A1 (en) * 2005-11-04 2007-05-24 Williams Christopher P Low radiocarbon nucleotide and amino acid dietary supplements
CN101316582A (zh) * 2005-11-30 2008-12-03 雀巢技术公司 治疗肌肉损失的方法
WO2007077995A1 (ja) * 2006-01-05 2007-07-12 Kyowa Hakko Kogyo Co., Ltd. 筋肉増量剤
GB0603975D0 (en) * 2006-03-01 2006-04-05 Etren Methods and agents for reducing oxidative stress
CN101420973A (zh) * 2006-03-15 2009-04-29 埃索谢尔制药公司 包含SODs和基于谷醇溶蛋白的肽片段的药物组份
FR2899065B1 (fr) * 2006-03-29 2008-07-18 Alain Dreyer Brevets Et Dev So Sod micro encapsulee et adsorbee sur support mineral et vegetal destinee a l'alimentation animale
DE102006046960A1 (de) * 2006-10-04 2008-04-10 Euro Allianz Pharma Gmbh Gesundheitsfördernde Nahrungsmittelzusammensetzung
US20080119386A1 (en) * 2006-11-22 2008-05-22 Carl Germano Nutritional formula for athletes' recovery
US8343541B2 (en) 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
EP2158462A4 (en) 2007-05-03 2010-05-05 Radiocarb Genetics Inc FOOD SUPPLEMENTS WITH LITTLE RADIO CARBON AND MANUFACTURING METHOD THEREFOR
ES2675942T3 (es) * 2007-09-27 2018-07-13 Biothera, Inc. Tratamiento con B-glucano de síntomas de infección del tracto respiratorio superior y del bienestar psicológico
WO2009099444A1 (en) * 2008-02-08 2009-08-13 Millennium Biotechnologies, Inc. Nutritional formula for athletes' recovery
JP6058263B2 (ja) 2008-04-11 2017-01-11 バーグ リミテッド ライアビリティ カンパニー 癌細胞においてアポトーシスを誘導する方法および使用
WO2010053854A1 (en) * 2008-11-06 2010-05-14 Altman Enterprises Llc Medication and treatment for disease
CN102481269B (zh) 2009-05-11 2015-10-07 博格有限责任公司 包含辅酶q10的药物组合物及其制备方法
EP2311449A1 (de) * 2009-10-14 2011-04-20 NÖM Aktiengesellschaft Oral verabreichbare nahrungsergänzende Zusammensetzung enthaltend Carnitin
CN113142581B (zh) 2010-12-23 2025-07-22 阿马曾提斯公司 用于改善线粒体功能的组合物和方法
WO2012097061A1 (en) * 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for improving skeletal muscle protein metabolism
US9198881B2 (en) 2011-01-18 2015-12-01 Stephen T. Sinatra Equine nutritional supplement
JP6092844B2 (ja) 2011-04-04 2017-03-08 バーグ エルエルシー 中枢神経系腫瘍の治療方法
BR112015025424A2 (pt) 2013-04-08 2017-07-18 Berg Llc tratamento de câncer usando terapias de combinação de coenzima q10
MX381399B (es) 2013-09-04 2025-03-12 Berg Llc Formulaciones de coenzima q10 y métodos de uso.
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
CN105709212A (zh) * 2016-01-29 2016-06-29 周瑞华 一种免疫平衡调节剂及其制备方法和应用
RU2656544C1 (ru) * 2017-07-07 2018-06-05 Общество с ограниченной ответственностью "Академия-Т" Функциональный продукт питания для коррекции психофизиологического состояния и нейромышечной передачи у спортсменов
CA3109188A1 (en) * 2018-08-10 2020-02-13 Maine Natural Health Company, Inc. Comestible compositions for promoting atp synthesis
CN110664824B (zh) * 2019-08-09 2021-01-01 北京佳博泰和健康科技有限公司 一种营养支持剂及其制备方法和用途
CN111820330A (zh) * 2020-07-17 2020-10-27 禹城保立康生物饲料有限公司 一种提高哺乳仔猪发育的母猪饲料
GB202308224D0 (en) 2023-06-01 2023-07-19 Amazentis Sa Formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5456924A (en) * 1988-12-23 1995-10-10 Immunotec Research Corporation Ltd. Method of treatment of HIV-seropositive individuals with dietary whey proteins
IT1258491B (it) * 1992-09-24 1996-02-26 Sigma Tau Ind Farmaceuti Impiego di l-carnitina e acil l-carnitine nel trattamento di pazienti affetti da aids e sindromi correlate e di pazienti asintomatici hiv- sieropositivi.
FR2729296B1 (fr) 1995-01-12 1997-03-28 Europlanaire Compositions pharmaceutiques comprenant une superoxyde dismutase
US5817329A (en) * 1997-02-28 1998-10-06 Gardiner; Paul T. Nutritional supplement for increased muscle size and strength for body builders
US6503506B1 (en) * 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients

Also Published As

Publication number Publication date
EP1432436A2 (en) 2004-06-30
EA006439B1 (ru) 2005-12-29
EA200400291A1 (ru) 2004-08-26
OA12649A (en) 2006-06-16
CA2457624A1 (en) 2003-02-20
WO2003013438A2 (en) 2003-02-20
US6503506B1 (en) 2003-01-07
JP2005501061A (ja) 2005-01-13
CN1568196A (zh) 2005-01-19
WO2003013438A3 (en) 2003-06-19
EP1432436A4 (en) 2005-02-09

Similar Documents

Publication Publication Date Title
WO2003013438A3 (en) Nutrient therapy for immuno-compromised patients
EP1439831B1 (en) Pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect
Mekkara nikarthil Sudhakaran et al. A review on nutritional composition, antinutritional components and health benefits of green gram (Vigna radiata (L.) Wilczek)
JP2005501061A5 (cg-RX-API-DMAC7.html)
US5973224A (en) Dietetical combination preparations
WO1999055326A1 (en) Method of treatment of glutathione deficient mammals
US20040071825A1 (en) Agglomerated granular protein-rich nutritional supplement
EP2205100B1 (en) Method for decreasing bitterness and improving taste of protein-free and hydrolyzed infant formulas
BR9711278A (pt) FÄrmula nutricional para pacientes com fenilcetonÚria
JP2009534323A5 (cg-RX-API-DMAC7.html)
RU2012126140A (ru) Питательные композиции, включающие высокобелковый компонент и экзогенные нуклеотиды
RU2008107342A (ru) Питание для пациентов, страдающих ожирением
Lee et al. Plant-based antioxidant peptides: impact on oxidative stress and gut microbiota
KR20050071562A (ko) 글루타민을 제공하기 위한 방법 및 조성물
Klatz The Official Anti-Aging Revolution: Stop the Clock Time is on Your Side for a Younger, Stronger, Happier You
Yavuz et al. The importance of animal proteins for human nutrition
Li et al. The anti-fatigue effect of black soybean peptide in mice
EP3984378A1 (en) Dietary supplement for sport use
CN120549226A (zh) 一种苯丙酮尿症人群用的组合物及其制备方法和应用
CN119214299A (zh) 一种肝病用特殊医学用途配方食品及其制备方法
CN103349331A (zh) 减肥饮料
CN109832530A (zh) 减肥饮料
Chen et al. We-P14: 409 Supplementation of L-arginine improve endothelium-dependent vasodilation in hypercholesterolemia with impaired vasodilation
Elliott et al. We-P14: 410 Intakes of phosphorus, magnesium and calcium in relation to blood pressure: The intermap study
Schwarz INTERACTIONS OF BRANCHED-CHAIN AMINO ACIDS IN THE IN VITRO MUSCLE.